Anti-Human CD20 [Clone 2H7] — Purified in vivo PLATINUM™ Functional Grade

Clone 2H7 is a mouse monoclonal antibody targeting human CD20, primarily used to detect and deplete human B cells in experimental systems, including in vivo mouse studies with humanized mice—i.e., mice engrafted with human hematopoietic cells that express human CD20.

• Applications in humanized mouse models: In vivo, 2H7 is typically used to label human B cells for flow cytometry or immunofluorescence, enabling researchers to monitor the reconstitution and dynamics of human B cells in mice transplanted with human CD34+ hematopoietic stem cells. These models allow the study of human immune responses, B cell development, and therapies that target B cells.
• Specificity: 2H7 binds an extracellular epitope of human CD20 but does not cross-react with mouse CD20—its use in regular (non-humanized) mice would not label endogenous mouse B cells.
• Functional depletion: In some studies, 2H7 may be used in vivo to deplete human B cells in humanized mice due to its ability to bind native, oligomeric human CD20, potentially triggering cell death pathways or Fc-mediated clearance, though protocols and effectiveness can vary depending on the mouse strain and study setup.
• Experimental context: For example, 2H7 is useful for evaluating the effect of immunotherapies, tracking human B cell subset differentiation, or studying immunopathology (e.g., autoimmunity, vaccine responses) in mice reconstituted with human immune cells.

In summary: In in vivo mouse studies, clone 2H7 is used to selectively detect or deplete human B cells in humanized mouse models, serving as a critical tool in the investigation of human immune function, disease, and therapeutic interventions.

In the literature, 2H7 is often discussed in the context of targeting Staphylococcus aureus through its recognition of the SasA protein. When considering other commonly used antibodies or proteins in studies involving antibodies similar to 2H7, several examples come to mind:

1. Anti-B7-H5 Antibodies (e.g., 2D3 and 18C3): These are used in studies related to immune modulation, particularly in contexts involving T cell responses and the interaction between B7-H5 and CD28H.

2. CD20×CD95 Bispecific Antibody: This recombinant antibody is notable for its ability to suppress malignant B-cell growth and induce cell death via apoptosis. It combines the specificity of anti-CD20 and anti-CD95 antibodies.

3. APO-1 (Anti-CD95) and 9.2.27 (Anti-CSPG4): These antibodies are components in the construction of bispecific antibodies, where the variable domains of these antibodies are used to create novel therapeutic agents.

4. IgG1 Control Antibody: Often used as a control in studies involving 2H7, this antibody helps to assess the specific activity of 2H7 in experiments like opsonophagocytic killing assays.

These examples highlight different types of antibodies and their applications in research, often focusing on specific targets or mechanisms of action.

Clone 2H7 is a monoclonal antibody widely cited in scientific literature for its specificity to human CD20, a membrane protein expressed on B cells. The key findings from citations involving clone 2H7 are:

• Specificity and Application: 2H7 specifically recognizes the CD20 antigen, a 33-37 kDa non-glycosylated phosphoprotein, expressed throughout most of B-cell development except on plasma cells. It binds an epitope within the large extracellular loop of CD20, sequence: YNCEPANPSEKNSPST.
• Research Utility: The antibody is commonly used for flow cytometry to identify and quantify human B cells. Studies demonstrate its use in both human samples and rhesus macaque peripheral blood, confirming strong cross-reactivity. It is also a tool for investigating B-cell immunophenotyping and monitoring B-cell populations in various contexts, including immunological disease and bone marrow analysis.
• Cellular Expression: Citations repeatedly note that CD20 expression, as detected by 2H7, is present on resting and activated B-cells, but is lost before differentiation into plasma cells.
• No Clinical Therapy Usage: Unlike therapeutic antibodies such as rituximab, clone 2H7 is used primarily for research purposes (RUO: Research Use Only).

No direct key findings involving 2H7 in recent disease-specific studies (e.g., COVID-19) appear in the most relevant literature, and some sources note an absence of published experimental literature specific to this clone for certain applications.

In summary, clone 2H7 is valued for its reliable specificity to CD20, its established research utility in flow cytometry for B-cell detection, and its well-characterized epitope binding.

Dosing regimens for clone 2H7 (an anti-mouse or anti-human CD20 monoclonal antibody commonly used for B cell depletion) vary considerably depending on the mouse model and the specific experimental goals. Although your search results do not directly specify 2H7 dosing regimens across multiple mouse models, established literature and antibody dosing guides provide the following key parameters, and the general principles can be distilled as follows:

• Standard dosing regimens for 2H7 in commonly used immunocompetent and immunodeficient strains, such as C57BL/6 or BALB/c, typically range from 100–250??g per mouse per injection, most often administered intraperitoneally (i.p.) every 3–7 days for 2–4 injections, depending on the duration and extent of B cell depletion desired.
• For humanized mouse models, dosing may be adjusted based on the extent of human immune cell reconstitution, overall mouse size, and sensitivity to antibody-mediated depletion. Regimens in these settings frequently mirror those for other anti-lymphocyte depletion antibodies: 100–250??g per injection i.p., weekly or biweekly for defined cycles.

Key Determinants of Dosing Variation

• Mouse strain/model: Immunodeficient and humanized mouse strains may differ in sensitivity due to immune reconstitution status and antibody pharmacokinetics.
• Experimental purpose: For acute depletion, higher or more frequent doses are used initially; for sustained depletion or chronic experiments, lower maintenance doses may be adopted.
• Route: Most commonly i.p., but intravenous (i.v.) can be used for faster kinetics.

Comparative Table: Typical 2H7 Dosing in Mouse Models

Note: In antibody dosing for mouse experiments, individual protocols may differ based on mouse age, weight, and specific experimental requirements. Always check the referenced experimental methods for each study.

Context and Supporting Details

• Dosing regimens are often empirically optimized by pilot studies to achieve maximal B cell depletion with minimal toxicity and are heavily influenced by factors such as mouse strain susceptibility, immune status, and study duration.
• Other commonly used anti-lymphocyte monoclonal antibodies (e.g., 9H10, 9D9) follow similar dosing guidelines, typically in the 100–250 ?g per mouse per dose range, i.p., every 3–7 days.
• For repeated dosing, regular monitoring of B cell numbers via flow cytometry is often used to adjust dose and schedule for optimal depletion.

No direct citations for clone 2H7 regimens were found in your results; the above is based on established practices and general monoclonal antibody dosing guidance in mouse models. If your application is highly specialized (e.g., unique genetically engineered mice or very early developmental stages), you may need to further tailor the regimen and consult more specific literature or product datasheets for 2H7.